Published in Dev Biol on October 08, 2011
Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol (2014) 1.43
Sox9 is required for prostate development and prostate cancer initiation. Oncotarget (2012) 1.09
Wnt signaling though beta-catenin is required for prostate lineage specification. Dev Biol (2012) 1.02
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Dietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet. Dermatoendocrinol (2012) 0.92
Visualization and quantification of mouse prostate development by in situ hybridization. Differentiation (2012) 0.89
Role of CEACAM1 and CEACAM20 in an in vitro model of prostate morphogenesis. PLoS One (2013) 0.87
Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. PLoS One (2013) 0.82
mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Res (2013) 0.82
The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) (2012) 0.81
Milk--A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation. Int J Mol Sci (2015) 0.80
Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Pten Regulates Epithelial Cytodifferentiation during Prostate Development. PLoS One (2015) 0.78
Patterned cell and matrix dynamics in branching morphogenesis. J Cell Biol (2017) 0.78
Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development (2017) 0.75
RET-mediated glial cell line derived neurotrophic factor signaling inhibits mouse prostate development. Development (2017) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
A global double-fluorescent Cre reporter mouse. Genesis (2007) 17.86
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
The culture of mature organs in a synthetic medium. Exp Cell Res (1959) 6.98
The two TORCs and Akt. Dev Cell (2007) 6.17
Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J (1996) 6.08
Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell (2002) 6.06
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell (2006) 5.19
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med (2008) 4.76
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol (2004) 4.70
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci (2003) 3.26
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem (1999) 3.17
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol (2005) 3.09
Retracted Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem (2003) 3.06
The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci (2008) 3.04
Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome (2002) 2.79
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev Cell (2010) 2.56
The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool (1978) 2.53
mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48
Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett (2004) 2.47
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
Temporal and spatial regulation of chemotaxis. Dev Cell (2002) 2.35
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem (1996) 1.85
Hepatocyte growth factor switches orientation of polarity and mode of movement during morphogenesis of multicellular epithelial structures. Mol Biol Cell (2003) 1.82
A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res (2008) 1.81
A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration. Dev Cell (2010) 1.74
Prostatic growth and development are regulated by FGF10. Development (1999) 1.74
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci U S A (2004) 1.67
Ras-mediated activation of the TORC2-PKB pathway is critical for chemotaxis. J Cell Biol (2010) 1.64
Control of HIF-1{alpha} and vascular signaling in fetal lung involves cross talk between mTORC1 and the FGF-10/FGFR2b/Spry2 airway branching periodicity clock. Am J Physiol Lung Cell Mol Physiol (2010) 1.63
FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol (2003) 1.53
Molecular signaling pathways that regulate prostate gland development. Differentiation (2008) 1.47
Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol (2002) 1.45
Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development (2007) 1.38
Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem (2003) 1.36
Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem (1999) 1.27
Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci U S A (2008) 1.26
Role of PI 3-kinase and PIP3 in submandibular gland branching morphogenesis. Dev Biol (2003) 1.24
Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res (2009) 1.20
Frs2alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for outflow tract morphogenesis. Development (2008) 1.16
The role of Fgf10 signaling in branching morphogenesis and gene expression of the rat prostate gland: lobe-specific suppression by neonatal estrogens. Dev Biol (2005) 1.16
TSC1/2 tumour suppressor complex maintains Drosophila germline stem cells by preventing differentiation. Development (2010) 1.13
Branching morphogenesis in the prostate gland and seminal vesicles. Differentiation (2006) 1.10
The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec (1973) 1.10
Branching morphogenesis of embryonic mouse lung epithelium in mesenchyme-free culture. Development (1995) 1.09
Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem (2007) 1.08
Growth, morphogenesis, and differentiation during mouse prostate development in situ, in renal grafts, and in vitro. Prostate (2005) 1.05
Distinct regulatory elements mediate the dynamic expression pattern of Nkx3.1. Dev Dyn (2005) 1.04
Gene expression profiling in the developing prostate. Differentiation (2008) 1.02
Role of androgens and fibroblast growth factors in prostatic development. Reproduction (2001) 1.01
Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. Differentiation (2007) 1.01
Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol (1996) 1.00
Substitution for mesenchyme by basement-membrane-like substratum and epidermal growth factor in inducing branching morphogenesis of mouse salivary epithelium. Development (1991) 0.99
PI3K-AKT pathway mediates growth and survival signals during development of fetal mouse lung. Tissue Cell (2004) 0.98
The mTOR signaling network: insights from its role during embryonic development. Curr Med Chem (2008) 0.93
Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem (2005) 0.93
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol (2008) 0.87
Analysis of prostatic bud induction by brief androgen treatment in the fetal rat urogenital sinus. J Endocrinol (1986) 0.85
Differentiation of rat neonatal ventral prostates grown in a serum-free organ culture system. Prostate (1997) 0.84
Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. II. Functional differentiation under serum-free conditions. In Vitro Cell Dev Biol (1990) 0.79
A morphometric analysis of rat ventral prostate in organ culture. Anat Rec (1983) 0.76
Non-invasive visualization of the lipid product of class I PI3K in transgenic mouse models. Biochem Soc Trans (2007) 0.76
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Tissue repair and stem cell renewal in carcinogenesis. Nature (2004) 6.28
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature (2008) 4.43
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 3.32
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol (2007) 2.53
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Anergic T cells are metabolically anergic. J Immunol (2009) 2.12
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci U S A (2011) 1.86
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res (2007) 1.76
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Chromatin "prepattern" and histone modifiers in a fate choice for liver and pancreas. Science (2011) 1.70
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 1.64
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 1.58
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Practical methods for tissue microarray construction. Methods Mol Med (2005) 1.54
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Molecular effects of genistein on male urethral development. J Urol (2011) 1.51
Telomere length as a risk factor for hereditary prostate cancer. Prostate (2013) 1.50
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 1.45
Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol (2009) 1.45
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol (2015) 1.45
Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol (2004) 1.44
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol (2014) 1.43
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate (2004) 1.43
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate (2008) 1.42
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol (2010) 1.39
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate (2005) 1.38